Sham Injection + FAI Insert
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Posterior Uveitis
Conditions
Posterior Uveitis, Intermediate Uveitis, Panuveitis
Trial Timeline
Jun 2, 2015 → Oct 4, 2019
NCT ID
NCT02746991About Sham Injection + FAI Insert
Sham Injection + FAI Insert is a phase 3 stage product being developed by EyePoint Pharmaceuticals for Posterior Uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02746991. Target conditions include Posterior Uveitis, Intermediate Uveitis, Panuveitis.
What happened to similar drugs?
4 of 4 similar drugs in Posterior Uveitis were approved
Approved (4) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02746991 | Phase 3 | Completed |
Competing Products
10 competing products in Posterior Uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab Prefilled Syringe | Eli Lilly | Approved | 39 |
| Adalimumab | AbbVie | Approved | 43 |
| Esomeprazole + Placebo | AstraZeneca | Approved | 43 |
| Azithromycin ophthalmic solution, 1% | Merck | Phase 2 | 27 |
| Sugammadex Injection [Bridion] + Placebo | Merck | Approved | 43 |
| FTY720 + Oral Corticosteroid | Novartis | Phase 2 | 27 |
| REGN7041 | Regeneron Pharmaceuticals | Phase 1/2 | 39 |
| Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) | Baxter | Phase 2 | 32 |
| ESK-001 | Alumis | Phase 2 | 21 |
| CF101 + Placebo | Can Fite Biopharma | Phase 2 | 17 |